Connecting oncology professionals with relevant clinical trials

Selected clinical trial

DECEMBER: De-escalation of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer in complete response

Sponsor: Unicancer

Phase: 3

Disease: Hormone receptor-positive, HER2-negative metastatic breast cancer, Locally advanced hormone receptor-positive, HER2-negative breast cancer

EU trial number: 2026-526319-12-00

Population: Adults with ER-positive, HER2-negative metastatic or locally advanced breast cancer who have achieved a complete response or partial response with sclerotic bone-only lesions for at least six months after at least two years of first-line CDK4/6 inhibitor plus aromatase inhibitor therapy; enrollment requires no detectable circulating tumor DNA at baseline.

Register Investigator Interest

Interested in offering this trial to suitable patients?